Boston Scientific Corporation (NYSE:BSX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Boston Scientific Corporation (NYSE:BSX) has received a consensus recommendation of “Moderate Buy” from the twenty-five brokerages that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, twenty have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $108.00.

A number of brokerages recently issued reports on BSX. JPMorgan Chase & Co. dropped their price objective on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Wall Street Zen raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday. Citigroup cut their price target on shares of Boston Scientific from $102.00 to $94.00 and set a “buy” rating for the company in a report on Wednesday. Truist Financial reduced their target price on Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research report on Thursday, February 5th. Finally, Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, February 4th.

Boston Scientific Stock Performance

NYSE:BSX opened at $69.15 on Friday. The company has a market cap of $102.61 billion, a P/E ratio of 35.64, a P/E/G ratio of 0.96 and a beta of 0.69. Boston Scientific has a twelve month low of $67.56 and a twelve month high of $109.50. The company’s 50-day moving average price is $82.47 and its 200-day moving average price is $93.39. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The company had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. Boston Scientific’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Neutral Sentiment: Zacks published a recap explaining why Boston Scientific dipped more than the broader market, noting recent volatility around the company. Useful for context on short‑term market reaction. Article Title
• Negative Sentiment: Citigroup lowered its price target for Boston Scientific to $94.00 — a formal analyst downgrade that can weigh on sentiment and may lead some funds to reprice positions. Article Title
• Negative Sentiment: Levi & Korsinsky (reported via PR Newswire) and others say a filed class action alleges Boston Scientific executives misrepresented U.S. electrophysiology procedure volumes — this is the substantive allegation that could lead to discovery, potential damages or settlement risk. Investors should watch pleadings and any company response. Article Title
• Negative Sentiment: Multiple plaintiff law firms (Rosen, Pomerantz, Glancy Prongay Wolke, Robbins Geller, Faruqi, Gross, Bernstein Liebhard, etc.) have issued shareholder alerts and deadline reminders (lead‑plaintiff motions due May 4, 2026). The coordinated outreach increases the likelihood of consolidated litigation and underscores ongoing legal scrutiny. Article Title

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. World Investment Advisors lifted its position in Boston Scientific by 2.2% during the 4th quarter. World Investment Advisors now owns 19,365 shares of the medical equipment provider’s stock worth $1,846,000 after acquiring an additional 411 shares during the period. Farmers National Bank acquired a new position in Boston Scientific during the fourth quarter worth $204,000. Corient Private Wealth LLC grew its stake in Boston Scientific by 2.6% in the 4th quarter. Corient Private Wealth LLC now owns 224,554 shares of the medical equipment provider’s stock valued at $21,437,000 after acquiring an additional 5,756 shares during the last quarter. Hsbc Holdings PLC boosted its stake in shares of Boston Scientific by 7.4% during the 4th quarter. Hsbc Holdings PLC now owns 3,612,252 shares of the medical equipment provider’s stock worth $344,735,000 after purchasing an additional 249,208 shares during the last quarter. Finally, Bayban acquired a new stake in shares of Boston Scientific during the fourth quarter worth $143,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.